StocksFundsScreenerSectorsWatchlists
VIR

VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

10.10USD0.00 (0.00%)Delayed as of 28 Mar 2024, 11:01 am ET

Market Summary

VIR
USD10.100.00
Delayedas of 28 Mar 2024, 11:01 am
0.00%

VIR Alerts

  • 3 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

VIR Stock Price

View Fullscreen

VIR RSI Chart

VIR Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-2.22

Price/Sales (Trailing)

15.83

EV/EBITDA

-1.84

Price/Free Cashflow

-1.7

VIR Price/Sales (Trailing)

VIR Profitability

Operating Margin

96.79%

EBT Margin

-728.93%

Return on Equity

-38.68%

Return on Assets

-32.05%

Free Cashflow Yield

-58.68%

VIR Fundamentals

VIR Revenue

Revenue (TTM)

86.2M

Rev. Growth (Yr)

-66.03%

Rev. Growth (Qtr)

536.11%

VIR Earnings

Earnings (TTM)

-615.1M

Earnings Growth (Yr)

-14.14%

Earnings Growth (Qtr)

29.03%

Breaking Down VIR Revenue

52 Week Range

8.7427.48
(Low)(High)

Last 7 days

-6.6%

Last 30 days

-1.9%

Last 90 days

-0.6%

Trailing 12 Months

-52.4%

How does VIR drawdown profile look like?

VIR Financial Health

Current Ratio

9.05

VIR Investor Care

Shares Dilution (1Y)

1.12%

Diluted EPS (TTM)

-4.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.1B490.7M118.8M86.2M
20222.3B2.1B1.9B1.6B
2021331.1M585.9M840.7M1.1B
202010.1M75.1M75.6M76.4M
201911.9M11.7M10.2M8.1M
20184.7M6.7M8.7M10.7M
20170002.7M

Tracking the Latest Insider Buys and Sells of Vir Biotechnology Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 26, 2024
scangos george a
sold
-206,522
11.6534
-17,722
-
Feb 22, 2024
hanly ann m.
acquired
-
-
32,500
evp & chief technology officer
Feb 22, 2024
de backer marianne
acquired
-
-
175,000
chief executive officer
Feb 22, 2024
lee sung
acquired
-
-
40,000
evp & chief financial officer
Feb 22, 2024
pang phillip
sold
-146,344
10.0456
-14,568
evp & chief medical officer
Feb 22, 2024
scangos george a
sold
-100,737
10.0456
-10,028
-
Feb 22, 2024
hanly ann m.
sold
-123,521
10.0456
-12,296
evp & chief technology officer
Feb 20, 2024
scangos george a
sold
-172,385
10.2172
-16,872
-
Feb 16, 2024
pang phillip
sold
-34,005
10.2396
-3,321
evp & chief medical officer
Feb 16, 2024
scangos george a
sold
-111,386
10.2396
-10,878
-

1–10 of 50

Which funds bought or sold VIR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
20.06
25,231
112,532
-%
Mar 11, 2024
VANGUARD GROUP INC
added
9.79
18,759,000
123,709,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
187
7,855,720
11,624,500
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.83
27,942
459,440
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
16,000
237,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
unchanged
-
12,653
181,653
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-1,098,000
-
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-50.92
-722
805
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-63.29
-1,340,000
872,000
-%
Feb 15, 2024
BARCLAYS PLC
added
7.89
612,000
4,475,000
-%

1–10 of 43

Are Funds Buying or Selling VIR?

Are funds buying VIR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VIR
No. of Funds

Unveiling Vir Biotechnology Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
sb investment advisers (uk) ltd
12.4%
16,684,041
SC 13G/A
Feb 13, 2024
vanguard group inc
9.14%
12,297,139
SC 13G/A
Jan 24, 2024
state street corp
5.14%
6,912,082
SC 13G
Jan 23, 2024
blackrock inc.
12.5%
16,864,579
SC 13G/A
Feb 14, 2023
softbank vision fund (aiv m1) l.p.
15.2%
20,259,535
SC 13G/A
Feb 09, 2023
vanguard group inc
7.58%
10,094,501
SC 13G/A
Jan 24, 2023
blackrock inc.
10.6%
14,136,628
SC 13G/A
Sep 13, 2022
arch venture fund ix, l.p.
9.7%
12,916,663
SC 13D/A
Sep 08, 2022
blackrock inc.
10.1%
13,384,194
SC 13G
May 10, 2022
arch venture fund ix, l.p.
14.5%
18,916,663
SC 13D/A

Recent SEC filings of Vir Biotechnology Inc

View All Filings
Date Filed Form Type Document
Feb 26, 2024
10-K
Annual Report
Feb 26, 2024
144
Notice of Insider Sale Intent
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
S-8
Employee Benefits Plan
Feb 22, 2024
8-K
Current Report
Feb 20, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of VIR?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Vir Biotechnology Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Vir Biotechnology Inc News

Latest updates
Defense World • 26 Mar 2024 • 08:49 am
Markets Insider • 19 Mar 2024 • 07:49 pm
Zacks Investment Research • 22 Feb 2024 • 08:00 am
Simply Wall St • 12 Feb 2024 • 08:00 am
Seeking Alpha • 2 months ago
The Motley Fool • 8 months ago

Vir Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue536.1%16,787,0002,639,0003,797,00062,957,00049,410,000374,557,000803,508,0001,232,459,000812,747,000103,616,000177,068,00089,401,0001,734,0001,928,00066,988,0005,718,000980,0001,403,0002,047,0003,661,0003,126,000
Cost Of Revenue2000.0%798,00038,00022,0001,907,0005,996,00022,253,00027,921,00090,149,00056,881,0007,836,0001,144,000----------
Costs and Expenses-17.7%155,803,000189,371,000218,983,000206,328,000199,912,000179,593,000184,593,000218,631,000240,999,000157,001,000116,051,000160,609,000---------
Operating Expenses----------157,001,000116,051,000160,609,000110,138,00089,543,00096,039,00077,628,00064,739,00049,083,00037,817,00034,431,00029,922,000
  S&GA Expenses4.9%43,090,00041,080,00047,101,00046,778,00038,743,00043,174,00041,590,00038,255,00055,777,00050,496,00028,781,00025,739,00023,043,00018,859,00016,386,00012,649,00011,808,0009,220,0008,011,0008,559,000-
  R&D Expenses-24.5%111,915,000148,253,000171,860,000157,643,000155,173,000114,166,000115,082,00090,227,000128,341,00098,669,00086,126,000134,870,00087,095,00070,684,00079,653,00064,979,00052,931,50039,863,00029,805,00025,872,000-
EBITDA Margin-30.7%-7.07-5.41-0.53-0.290.470.790.650.710.51-0.11-0.50-1.16---------
Income Taxes-48.9%-4,784,000-3,213,000-2,848,000-2,232,000-50,035,00042,420,000-157,228,000403,286,00020,635,000334,00053,000196,000-30,00022,00046,00016,000149,000-13,00019,000--
Earnings Before Taxes27.5%-120,757,000-166,626,000-197,623,000-143,188,000-151,638,000217,732,000-233,721,000921,907,000545,889,000110,762,00061,866,000-168,715,000-105,679,000-84,587,000-31,121,000-77,224,000-63,622,500-48,327,000-33,909,000-28,670,000-
EBT Margin-31.4%-7.29-5.55-0.56-0.300.470.780.640.710.50-0.12-0.51-1.18---------
Net Income29.0%-115,973,000-163,413,000-194,775,000-140,956,000-101,603,000175,312,000-76,493,000518,621,000525,254,000110,428,00061,813,000-168,911,000-105,649,000-84,609,000-31,167,000-77,240,000-63,771,000-48,314,000-33,928,000-28,670,000-26,393,000
Net Income Margin-41.2%-7.14-5.06-0.53-0.140.320.620.520.520.48-0.12-0.51-1.18---------
Free Cashflow31.4%-109,462,000-159,543,000-398,704,000-132,649,00022,530,00098,909,000939,538,000534,248,000-5,372,000-111,819,000137,981,000-90,196,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets-6.2%1,9192,0452,2442,6662,8022,6962,6192,8871,9541,2101,0581,136919943672477512423192
  Current Assets-10.2%1,5881,7691,9462,3592,5192,4142,2882,5681,5631,066862993772850579378403338118
    Cash Equivalents-46.6%2424526678258499641,50581234871574252145146337216812394.0059.00
  Net PPE-3.3%96.0099.0010410410610085.0066.0043.0027.0020.0017.0018.0017.0016.0016.0016.0015.0012.00
  Goodwill-0.2%17.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.00
Liabilities-11.1%32937043469572454666788652233432048520213110897.0088.0067.0062.00
  Current Liabilities6.3%17516522648551130847870234123414636199.0077.0055.0056.0059.0044.0040.00
Shareholder's Equity-5.1%1,5901,6751,8101,9712,0782,1501,9522,0011,432876737651717812564380424--
  Retained Earnings-95.2%-237-12142.00236377479304380-138-663774-836-667-561-476-445-368-304-193
  Additional Paid-In Capital1.7%1,8291,7991,7721,7381,7101,6831,6561,6261,5721,5411,5131,4881,3851,3741,04182679324.0015.00
Shares Outstanding0.2%135134134134133132132132130131130128-------
Minority Interest----0.00---------------
Float---1,800---2,000---2,700---2,300----
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations30.7%-107-155-389-12535.001189605508.00-105140-89.53-82.05-49.84-10.64-48.41-38.88-36.95-24.30-29.49-
  Share Based Compensation4.9%28.0027.0031.0025.0025.0025.0027.0025.0024.0023.0021.0015.0010.009.006.003.003.002.001.002.00-
Cashflow From Investing-77.8%-104-58.9523098.00-153-662-272-105-37774.0075.0088.0061.00-18511.00104-73.7747.0044.00-274-
Cashflow From Financing506.5%2.000.003.002.002.002.003.0028.006.004.004.0088.00-0.263242050.001302.000.00317-

VIR Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 86,180,000$ 1,615,797,000$ 1,095,415,000
Operating expenses:   
Cost of revenue2,765,000146,319,00065,865,000
Research and development589,671,000474,648,000448,006,000
Selling, general and administrative178,049,000161,762,000160,793,000
Total operating expenses770,485,000782,729,000674,664,000
(Loss) income from operations(684,305,000)833,068,000420,751,000
Other income (loss):   
Change in fair value of equity investments(21,888,000)(111,140,000)138,049,000
Interest income86,990,00028,092,000439,000
Other (expense) income, net(8,991,000)4,260,000(9,437,000)
Total other income (loss)56,111,000(78,788,000)129,051,000
(Loss) income before benefit from (provision for) income taxes(628,194,000)754,280,000549,802,000
Benefit from (provision for) income taxes13,077,000(238,443,000)(21,218,000)
Net (loss) income(615,117,000)515,837,000528,584,000
Net loss attributable to noncontrolling interest(56,000)00
Net (loss) income attributable to Vir$ (615,061,000)$ 515,837,000$ 528,584,000
Net income (loss) per share attributable to Vir, basic (in USD per share)$ (4.59)$ 3.89$ 4.07
Net income (loss) per share attributable to Vir, diluted (in USD per share)$ (4.59)$ 3.83$ 3.96
Weighted-average shares outstanding, basic (in shares)134,130,924132,606,767129,884,967
Weighted-average shares outstanding, diluted (in shares)134,130,924134,810,908133,437,126
Collaboration revenue   
Revenues:   
Total revenues$ 37,266,000$ 1,505,469,000$ 917,194,000
Contract revenue   
Revenues:   
Total revenues2,228,00052,714,000169,874,000
License revenue from a related party   
Revenues:   
Total revenues022,289,0000
Grant revenue   
Revenues:   
Total revenues$ 46,686,000$ 35,325,000$ 8,347,000

VIR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 241,576$ 848,631
Short-term investments1,270,9801,521,517
Restricted cash and cash equivalents, current13,26812,681
Equity investments9,85331,892
Prepaid expenses and other current assets52,549104,356
Total current assets1,588,2262,519,077
Intangible assets, net22,56532,755
Goodwill16,93716,937
Property and equipment, net96,018105,609
Operating right-of-use assets71,18282,557
Restricted cash and cash equivalents, noncurrent6,4486,656
Long-term investments105,27523,927
Other assets12,40914,570
TOTAL ASSETS1,919,0602,802,088
CURRENT LIABILITIES:  
Accounts payable6,3346,422
Accrued and other liabilities104,220489,090
Deferred revenue, current64,85315,517
Total current liabilities175,407511,029
Deferred revenue, noncurrent1,52653,207
Operating lease liabilities, noncurrent111,673123,837
Contingent consideration, noncurrent25,96024,937
Other long-term liabilities14,25811,115
TOTAL LIABILITIES328,824724,125
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and 2022, respectively; no shares issued and outstanding as of December 31, 2023 and 202200
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 134,781,286 and 133,236,687 shares issued and outstanding as of December 31, 2023 and 2022, respectively1313
Additional paid-in capital1,828,8621,709,835
Accumulated other comprehensive loss(815)(9,122)
(Accumulated deficit) retained earnings(237,824)377,237
TOTAL STOCKHOLDERS’ EQUITY1,590,2362,077,963
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 1,919,060$ 2,802,088
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
 CEO
 WEBSITEwww.vir.bio
 EMPLOYEES576

Vir Biotechnology Inc Frequently Asked Questions


What is the ticker symbol for Vir Biotechnology Inc? What does VIR stand for in stocks?

VIR is the stock ticker symbol of Vir Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vir Biotechnology Inc (VIR)?

As of Wed Mar 27 2024, market cap of Vir Biotechnology Inc is 1.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers. The fair value of Vir Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vir Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vir Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether VIR is over valued or under valued. Whether Vir Biotechnology Inc is cheap or expensive depends on the assumptions which impact Vir Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIR.

What is Vir Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, VIR's PE ratio (Price to Earnings) is -2.22 and Price to Sales (PS) ratio is 15.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIR PE ratio will change depending on the future growth rate expectations of investors.